Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with AchondroplasiaGlobeNewsWire • 03/31/25
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/18/25
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care ConferenceGlobeNewsWire • 02/24/25
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUsGlobeNewsWire • 02/12/25
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025GlobeNewsWire • 02/05/25
Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)Seeking Alpha • 01/29/25
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/12/25
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/25
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in AdultsGlobeNewsWire • 12/19/24
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26GlobeNewsWire • 12/16/24
FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyGlobeNewsWire • 12/12/24
Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian MarketsGlobeNewsWire • 12/10/24
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyGlobeNewsWire • 09/30/24
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024GlobeNewsWire • 09/30/24